C. Michael Gibson/LinkedIn; Ulf Landmesser/FRIEDE SPRINGER
Cardiovascular
Prevention
Center Charité
Nov 9, 2025, 12:33
C Michael Gibson and Ulf Landmesser Discuss Insights from CLOSURE-AF trial
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Ulf Landmesser and I discuss the CLOSURE-AF trial:
In AF patients with high risk of stroke and bleeding, is LAA occlusion as effective and safe compared to optimal medical therapy?
View it here.”
Stay updated with Hemostasis Today.
-
Feb 17, 2026, 09:04Mahesan Subramaniam: A Heart Attack Is a Long Story That Ends Fast
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood